Precision Biosciences cleared to treat more patients in Duchenne gene-editing study

Precision Biosciences has won the backing of an independent safety panel to treat further patients in the opening stage of its Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD, its gene-editing candidate for Duchenne muscular dystrophy. The company announced the decision on 5 November 2026.

The panel's view rests on the first patient dosed, who was followed for eight weeks. Precision says that over this period there were no serious adverse events and no events of the kind flagged for special monitoring. The company has not said how many patients Part 1 will enrol, what dose levels are being tested, or which efficacy measures it will report.

For now the commercial picture is unchanged: no financial terms, funding commitments or market estimates accompanied the news. What the decision does is let the programme move beyond a single-patient dataset, a step that, as a matter of general context, tends to set the pace of early-phase gene-editing trials. Precision expects to share safety and efficacy updates through 2027.